As a result of a M&A, our client acquired a drug approved in other jurisdictions to treat adult leukemia. Our role was to develop a comprehensive Canadian business evaluation supporting a "Go/No Go" decision. Within three weeks, we able to interview stakeholders including KOL's at Princess Margaret Hospital, conduct an online survey with AML specialists across Canada and present the final business case to the management board.
Our client was preparing to introduce their first oncology drug to the Canadian market. Our mandate was to:
Identify KOL's and “rising stars” using the OncoMed mapping platform
Develop account targeting strategy
Create a segmented list of oncologists/haematologists managing the specific disease
Assist in sales force and MSL right sizing
We have worked with several cients to develop business reviews in advance of strategic planning sessions. The reviews identify via stakeholder engagement critical success factors, key issues and recommendations from a totally independent and unbiased perspective. Many strategic planning experts, including OncoMed, advocate the benefits of an "outsider looking in" as it may bring fresh perspective to the planning process while also challenging the permanence of group think.
Conducted Canadian evaluation of several biomarkers/diagnostics including MammaPrint®
Environmental scans/ Strategic reviews: Myeloma, CLL, AML , NHL, breast cancer, lung cancer, BMT, supportive care (CINV)
Market Research
Conducted interviews and surveys with hospital infusion clinic decision makers to better understand the current landscape and how best to incorporate a new therapy into oncology clinics.
Oncologist/hematologist research to better understand their perceptions/attitudes towards private infusion clinics.
Working on behalf of Lymphoma Foundation Canada, surveyed over 100 lymphoma patients that led to the first ever Canadian Lymphoma Report Card
Myeloma landscaping - interviews with Canada's leading myeloma specialists
Oncology sales force and corporate image evaluation: Surveyed hematologists annually to obtain their ratings of several organizations promoting medications in the malignant hematology sector. Similar research conducted with 60 urologists / oncologists "detailed" by reps from four companies promoting prostate cancer medications.
Focus groups with physicians, pharmacists, nurses and patients to test product profiles, secure customer feedback regarding critical issues and to identify unmet needs.
